Revumenib
- Generic Name
- Revumenib
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C32H47FN6O4S
- CAS Number
- 2169919-21-3
- Unique Ingredient Identifier
- LZ0M43NNF2
- Associated Conditions
- -
- Associated Therapies
- -
Revumenib in Combination With 7+3 + Midostaurin in AML
- Conditions
- AML With Gene MutationsAMLLeukemiaAML, AdultAcute Myeloid Leukemia
- Interventions
- First Posted Date
- 2024-03-15
- Last Posted Date
- 2024-12-31
- Lead Sponsor
- Maximilian Stahl, MD
- Target Recruit Count
- 22
- Registration Number
- NCT06313437
- Locations
- ๐บ๐ธ
Brigham and Women's Hospital, Boston, Massachusetts, United States
๐บ๐ธDana-Farber Cancer Institute, Boston, Massachusetts, United States
A Multi-Site Break Through Cancer Trial: Phase II Study Investigating Dual Inhibition of BCL2 and Menin in AML MRD Using the Combination of Venetoclax and Revumenib
- First Posted Date
- 2024-02-29
- Last Posted Date
- 2025-01-10
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 8
- Registration Number
- NCT06284486
- Locations
- ๐บ๐ธ
MD Anderson Cancer Center, Houston, Texas, United States
Expanded Access Program for Revumenib
- Conditions
- Relapsed/Refractory Acute Leukemia
- First Posted Date
- 2023-06-26
- Last Posted Date
- 2025-01-10
- Lead Sponsor
- Syndax Pharmaceuticals
- Registration Number
- NCT05918913
- Locations
- ๐บ๐ธ
UCLA, UCLA RRMC, Drug Information Center, Department of Pharmaceutical Services Drug Supply Shipment, Los Angeles, California, United States
๐บ๐ธUniversity of California, San Francisco, San Francisco, California, United States
๐บ๐ธRady Children's Hospital, San Diego, California, United States
Testing the Addition of an Anti-cancer Drug, SNDX-5613, to the Standard Chemotherapy Treatment (Daunorubicin and Cytarabine) for Newly Diagnosed Patients With Acute Myeloid Leukemia That Has Changes in NPM1 or MLL/KMT2A Gene
- Conditions
- Acute Myeloid Leukemia With KMT2A RearrangementAcute Myeloid Leukemia With NPM1 Mutation
- Interventions
- Procedure: Biospecimen CollectionProcedure: Bone Marrow AspirationProcedure: Bone Marrow BiopsyDrug: CytarabineDrug: DaunorubicinProcedure: Multigated Acquisition ScanDrug: RevumenibProcedure: Transthoracic Echocardiography
- First Posted Date
- 2023-06-02
- Last Posted Date
- 2024-12-27
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 28
- Registration Number
- NCT05886049
- Locations
- ๐บ๐ธ
UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange, California, United States
๐บ๐ธUM Sylvester Comprehensive Cancer Center at Aventura, Aventura, Florida, United States
๐บ๐ธUM Sylvester Comprehensive Cancer Center at Coral Gables, Coral Gables, Florida, United States
Evaluation of Revumenib in Participants With Colorectal Cancer and Other Solid Tumors
- Conditions
- Colorectal CancerSolid Tumors
- Interventions
- Drug: RevumenibDrug: Chemotherapy
- First Posted Date
- 2023-02-16
- Last Posted Date
- 2025-01-10
- Lead Sponsor
- Syndax Pharmaceuticals
- Target Recruit Count
- 42
- Registration Number
- NCT05731947
- Locations
- ๐บ๐ธ
Honor Health Research Institute, Scottsdale, Arizona, United States
๐บ๐ธMassachusetts General Hospital, Boston, Massachusetts, United States
๐บ๐ธMemorial Sloan Kettering Cancer Center, Manhattan, New York, United States
Study of Radiolabeled Revumenib in Adults With Acute Leukemia
- First Posted Date
- 2022-06-07
- Last Posted Date
- 2025-01-10
- Lead Sponsor
- Syndax Pharmaceuticals
- Target Recruit Count
- 9
- Registration Number
- NCT05406817
- Locations
- ๐บ๐ธ
MD Anderson Cancer Center, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.